Orlistat — Discount Pricing

Other medications in Diabetes & Metabolism

• Phentermine
• Phentermine-Topiramate
• Pioglitazone
• Repaglinide
• Saxagliptin
• Semaglutide
• Semaglutide (Obesity)
• Sitagliptin

About Orlistat

Orlistat is a medication prescribed to help individuals manage their weight, typically alongside a reduced-calorie diet and increased physical activity. For those looking to make their weight management journey more accessible, TheDrugClub membership can provide significant savings on Orlistat and many other prescription medications, helping you prioritize your health without breaking the bank.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Orlistat is approved for (FDA label)

XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared.

Source: Read the full FDA label on DailyMed. Label effective date: January 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Orlistat (FDA label)

XENICAL 120 mg turquoise capsules imprinted with XENICAL 120 in black ink. Capsules: 120 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 6240792b-9224-2d10-e053-2a91aa0a2c3e. SPL document ID: 4fd710c5-6147-498a-ade9-0cce6e1513c7. Label effective date: January 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Orlistat (FDA label)

Most common treatment emergent adverse reactions (≥5% and at least twice that of placebo) include oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation and fecal incontinence. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact the Safety Call Center at 1-888-236-5445 or FDA at 1‑800‑FDA‑1088 (1-800-332-1088) or www.fda.gov/medwatch. 6.1 Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients.

Source: FDA prescribing information (DailyMed). Set ID: 6240792b-9224-2d10-e053-2a91aa0a2c3e. SPL document ID: 4fd710c5-6147-498a-ade9-0cce6e1513c7. Label effective date: January 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Orlistat (FDA label)

XENICAL is contraindicated in: Pregnancy [see Use in Specific Populations (8.1) ] Patients with chronic malabsorption syndrome Patients with cholestasis Patients with known hypersensitivity to XENICAL or to any component of this product Pregnancy ( 4 , 8.1 ) Chronic malabsorption syndrome ( 4 ) Cholestasis ( 4 ) Known hypersensitivity to XENICAL or to any component of this product ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 6240792b-9224-2d10-e053-2a91aa0a2c3e. SPL document ID: 4fd710c5-6147-498a-ade9-0cce6e1513c7. Label effective date: January 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Orlistat (FDA label)

XENICAL has drug interactions and can decrease vitamin absorption. ( 5.1 , 7 ) Take a multivitamin supplement that contains fat-soluble vitamins to ensure adequate nutrition. ( 5.1 ) Rare cases of severe liver injury with hepatocellular necrosis or acute hepatic failure have been reported. ( 5.2 ) Patients may develop oxalate nephrolithiasis and oxalate nephropathy following treatment with XENICAL. Monitor renal function in patients at risk for renal insufficiency.

Source: FDA prescribing information (DailyMed). Set ID: 6240792b-9224-2d10-e053-2a91aa0a2c3e. SPL document ID: 4fd710c5-6147-498a-ade9-0cce6e1513c7. Label effective date: January 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Orlistat (FDA label)

Cyclosporine: Reduction in cyclosporine plasma levels was observed when XENICAL was coadministered with cyclosporine. ( 7.1 ) Fat-soluble Vitamin Supplements and Analogues: All patients should take a daily multivitamin that contains vitamins A, D, E, K, and beta-carotene. ( 7.2 ) Levothyroxine: Patients treated concomitantly with XENICAL and levothyroxine should be monitored for changes in thyroid function. ( 7.3 ) Warfarin: Patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters. ( 7.4 ) Amiodarone: A reduction in exposure to amiodarone was observed when XENICAL was co-administered. ( 7.5 ) Antiepileptic Drugs: Convulsions have been reported in patients taking XENICAL with antiepileptic drugs. Patients should be monitored for possible changes in frequency or severity of convulsions. ( 7.6 ) Antiretroviral Drugs: Loss of virological control has been reported in HIV-infected patients.

Source: FDA prescribing information (DailyMed). Set ID: 6240792b-9224-2d10-e053-2a91aa0a2c3e. SPL document ID: 4fd710c5-6147-498a-ade9-0cce6e1513c7. Label effective date: January 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.